Owens & Minor (NYSE:OMI) Updates Q4 2024 Earnings Guidance

Owens & Minor (NYSE:OMI - Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 0.520-0.550 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Owens & Minor also updated its FY 2024 guidance to 1.500-1.530 EPS.

Owens & Minor Price Performance

Shares of OMI stock traded down $0.22 during trading on Thursday, hitting $8.68. The company had a trading volume of 943,329 shares, compared to its average volume of 948,265. The stock's 50-day moving average is $13.60 and its two-hundred day moving average is $14.20. The stock has a market capitalization of $669.31 million, a price-to-earnings ratio of -13.20, a price-to-earnings-growth ratio of 0.40 and a beta of 0.48. The company has a quick ratio of 0.45, a current ratio of 1.09 and a debt-to-equity ratio of 2.11. Owens & Minor has a 52 week low of $8.58 and a 52 week high of $28.35.

Owens & Minor (NYSE:OMI - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.01. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.68 billion. During the same quarter in the prior year, the firm earned $0.44 EPS. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, analysts predict that Owens & Minor will post 1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Barclays dropped their price target on Owens & Minor from $18.00 to $14.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 5th. UBS Group cut their target price on Owens & Minor from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, November 5th. Citigroup decreased their price target on shares of Owens & Minor from $21.00 to $18.50 and set a "buy" rating on the stock in a research note on Tuesday, November 5th. Finally, Robert W. Baird reduced their target price on shares of Owens & Minor from $15.00 to $14.00 and set a "neutral" rating on the stock in a report on Tuesday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, Owens & Minor currently has a consensus rating of "Hold" and a consensus target price of $18.50.

Insiders Place Their Bets

In related news, CFO Jonathan A. Leon sold 5,282 shares of Owens & Minor stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $11.82, for a total value of $62,433.24. Following the sale, the chief financial officer now owns 130,822 shares in the company, valued at $1,546,316.04. The trade was a 3.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.62% of the company's stock.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.